Will Emerging Agents Disrupt the Psoriatic Arthritis Market?

Published by: Decision Resources

Published: Mar. 27, 2009 - 33 Pages

Table of Contents

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Overview of Psoriatic Arthritis

Disease Description and Etiology

Symptoms

Diagnosis and Disease Progression

Epidemiology

Overview

Disease Defi nition

Methods

Current Therapies for Psoriatic Arthritis

Disease-Modifying Antirheumatic Drugs

Tumor Necrosis Factor-Alpha Inhibitors

Nonsteroidal Anti-Infl ammatory Drugs

Emerging Therapies for Psoriatic Arthritis

Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen’s Golimumab

Bristol-Myers Squibb’s Orencia

Centocor/Medarex’s Stelara

Celgene’s Apremilast

Novartis’s AIN-457

Psoriatic Arthritis Market: 2007 Statistics and Future Outlook

Bibliography

Tables

1. Major Mediators in the Pathogenesis of Psoriatic Arthritis

2. Summary of the 2006 CASPAR Criteria for the Classifi cation of Psoriatic Arthritis

3. Conventional Disease-Modifying Antirheumatic Drugs Commonly Used to Treat Psoriatic Arthritis

4. TNF-á Inhibitors Approved for the Treatment of Psoriatic Arthritis

5. Nonsteroidal Anti-Infl ammatory Agents Commonly Prescribed for Psoriatic Arthritis

6. Emerging Therapies to Treat Psoriatic Arthritis

7. Sales of Therapies to Treat Psoriatic Arthritis, 2007

Figures

1. Rheumatologist-Estimated Percentage of Patients with Specifi c Psoriatic Arthritis Symptoms

2. Prevalent Cases of Psoriatic Arthritis in the United States and Europe, 2007-2017

3. Survey Question: Please indicate your fi rst-, second-, and third-line therapy choice for psoriatic arthritis

4. Survey Question: What percentages of your psoriatic arthritis patients move to/add on a second-line therapy within the following time frames?

5. Survey Question: What are the reasons why you do not prescribe TNF-á inhibitors as a fi rst-line therapy for psoriatic arthritis?

6. Survey Question: If golimumab is approved for psoriatic arthritis, will you prescribe it to your patients?

7. Survey Question: If apremilast is approved for psoriatic arthritis, will you prescribe it to your patients?

8. Survey Question: If AIN-457 is approved for psoriatic arthritis, will you prescribe it to your patients?

Abstract

• PsA a chronic, debilitating disease that is both • underdiagnosed and undertreated. What are the symptoms of PsA? How is the disease diagnosed? What are the risk factors for the disease? How many people in the United States and Europe have PsA? How will this population grow over the next ten years?
• TNF-á inhibitors were the fi rst agents to receive approval for PsA. How are TNF-á inhibitors incorporated into rheumatologists’ treatment choices? How will emerging treatments compete with TNF-á inhibitors?
• Because of the high cost and increased use of TNF-á inhibitors, the PsA market has experienced strong growth over the past few years. Will the PsA market continue to grow? How will emerging agents perform in the market?

• Primary research: survey of U.S. rheumatologists.
• Overview of PsA: etiology, symptoms, and diagnosis.
• Current treatments: nonsteroidal anti-infl ammatory agents, conventional diseasemodifying antirheumatic drugs, and TNF-á inhibitors.
• Epidemiology: prevalent cases of PsA in the United States, France, Germany, Italy, Spain, and the United Kingdom.
• Emerging agents: Centocor/Schering-Plough/Janssen/Mitsubishi Tanabe’s golimumab; Bristol-Myers Squibb’s Orencia; Centocor/Medarex’s Stelara; Celgene’s apremilast; and Novartis’s AIN-457.
• Market overview: 2007 PsA market; outlook for current and emerging agents.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.